 Mereo BioPharma Group plc NASDAQ: MREO, AIM: MPH today announces the completion of a 70 million 56 million private placement the Fundraising with a number of new and existing U.S based institutional and accredited investors. OrbiMed led the Fundraising with participants including Vivo Capital, Surveyor Capital a Citadel company, Pontifax Venture Capital, Samsara BioCapital, Commodore Capital, and funds managed by Janus Henderson Investors alongside existing investors Boxer Capital of Tavistock Group and Aspire Capital Fund, LLC. Private placement completed raising 70.0 million 56.0 million before expenses. 